Follow-up height after discontinuation of growth hormone treatment in children with intrauterine growth retardation.

What Was Tested

This randomized controlled trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

This study was designed to evaluate the growth of children with IUGR after discontinuation of a two-year trial of GH treatment.

Why It Was Studied

Growth hormone (GH) treatment has been used in children with intrauterine growth retardation (IUGR) to promote growth with success in several short- and long-term clinical trials.

Intermittent GH therapy has also been advocated in children with IUGR.

Who Took Part

The abstract describes 2 children taking part.

PubMed indexes the participants as young children and children, both men and women.

How the Study Was Run

In design terms this was a randomized study.

Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

What Was Measured

The subject headings attached to it are Age Determination by Skeleton, Body Height, Bone Development, Fetal Growth Retardation, Glycated Hemoglobin, Growth and Human Growth Hormone.

What This Means in Plain Language

The paper is a randomized study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 2 children.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2002 (Journal of pediatric endocrinology & metabolism : JPEM), a journal based in Germany.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.